# Bevacizumab

## Avastin inj 100mg/4mL

##### 

| TAH Drug Code      | [IAVA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IAVA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | In combination with irinotecan/5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin as 1st-line treatment of metastatic carcinoma of the colon or rectum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. Continue treatment until disease progression or unacceptable toxicity.  [Metastatic Colorectal Cancer (mCRC)]- 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination withfluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Avastin-containing regimen.- 10 mg/kg every 2 weeks or 15 mg/kg every 2 weeks for Avastin-naive patients as second-line therapy.  [Metastatic Breast Cancer (mBC)] 10 mg/kg every 2 weeks  [Glioblastoma] 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks  [Non-Squamous Non-Small Cell Lung Cancer (NSCLC)] 15 mg/kg every 3 weeks  [Ovarian (epithelial), fallopian tube, or primary peritoneal cancer] - Stage III/IV disease following initial surgical resection: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles, followed by bevacizumab 15 mg/kg every 3 weeks (monotherapy), for a total of up to 22 cycles (=15 months) or until disease progression (whichever occurs earlier)- Platinum-sensitive recurrent: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6-10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity- Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks (in combination with paclitaxel, doxorubicin [liposomal], or topotecan)  [Cervical cancer] 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan) |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanised antibodies; untreated CNS metastases.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Asthenia, pain, abdominal pain, headache, hypertension, diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, upper respiratory infection, epistaxis, dyspnea, exfoliative dermatitis, proteinuria. Rarely, GI perforation, hemorrhage, arterial thromboembolism, wound healing complications, hypertensive crises, nephrotic syndrome, CHF.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

